How do you treat a patient who develops metastatic prostate CA while on enzalutamide or apalutamide for originally M0 CRPC?

Most patients in this setting actually have mCRPC but very low volume disease. Occasionally this can be local/regional only but most PET imaging studies suggest that M0 CRPC is comprised of metastatic disease below the limits of detection of conventional CT and bone scan imaging. Thus I manage these...